Expression patterns of signaling lymphocytic activation molecule family members in peripheral blood mononuclear cell subsets in patients with systemic lupus erythematosus. by Karampetsou, M.P. et al.
RESEARCH ARTICLE
Expression patterns of signaling lymphocytic
activation molecule family members in
peripheral blood mononuclear cell subsets in
patients with systemic lupus erythematosus
Maria P. Karampetsou1☯, Denis Comte1,2☯, Katalin Kis-Toth1, Vasileios C. Kyttaris1,
George C. Tsokos1*
1 Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
Massachusetts, United States of America, 2 Division of Immunology and Allergy, Centre Hospitalier
Universitaire Vaudois, Lausanne, Switzerland
☯ These authors contributed equally to this work.
* gtsokos@bidmc.harvard.edu
Abstract
Genome-wide linkage analysis studies (GWAS) studies in systemic lupus erythematosus
(SLE) identified the 1q23 region on human chromosome 1, containing the Signaling Lym-
phocytic Activation Molecule Family (SLAMF) cluster of genes, as a lupus susceptibility
locus. The SLAMF molecules (SLAMF1-7) are immunoregulatory receptors expressed pre-
dominantly on hematopoietic cells. Activation of cells of the adaptive immune system is
aberrant in SLE and dysregulated expression of certain SLAMF molecules has been
reported. We examined the expression of SLAMF1-7 on peripheral blood T cells, B cells,
monocytes, and their respective differentiated subsets, in patients with SLE and healthy
controls in a systematic manner. SLAMF1 levels were increased on both T cell and B cells
and their differentiated subpopulations in patients with SLE. SLAMF2 was increased on SLE
CD4+ and CD8+ T cells. The frequency of SLAMF4+ and SLAMF7+ central memory and
effector memory CD8+ T cells was reduced in SLE patients. Naïve CD4+ and CD8+ SLE T
cells showed a slight increase in SLAMF3 levels. No differences were seen in the expres-
sion of SLAMF5 and SLAMF6 among SLE patients and healthy controls. Overall, the
expression of various SLAMF receptors is dysregulated in SLE and may contribute to the
immunopathogenesis of the disease.
Introduction
Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease characterized by
a loss of tolerance to self antigens, the production of autoantibodies and inflammation of
multiple organs [1–3]. Genome wide association studies (GWAS) in human SLE have identi-
fied the 1q23 region on chromosome 1, which contains the SLAMF (Signaling Lymphocytic
Activation Molecule Family) cluster of genes, as a susceptibility locus for lupus [4, 5]. In
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addition, the syntenic genomic region 1H3 has been described to be associated with autoim-
mune manifestations in three different murine models of spontaneous lupus, namely the
NZB/W F1, NZM and BXSB strains [6–8]. Specific SLAMF variants and single nucleotide
polymorphisms have been associated with autoimmune diseases, such as rheumatoid arthri-
tis, and/or specific lupus manifestations, such as neuropsychiatric and renal disease, thus
further underscoring the potential involvement of the SLAMF molecules in autoimmunity
[9–12].
The SLAMF gene cluster encodes seven co-regulatory receptors: SLAMF1 (CD150, SLAM),
SLAMF2 (CD48), SLAMF3 (CD229, Ly9), SLAMF4 (CD244, 2B4), SLAMF5 (CD84),
SLAMF6 (CD352, NTBA, Ly108) and SLAMF7 (CD319, CRACC, CS1). SLAMF8 (CD353,
BLAME) and SLAMF9 (CD84-H1) are located outside, but in close proximity to the SLAMF
locus. SLAMF molecules are mainly expressed on hematopoietic cells. They are type I trans-
membrane glycoprotein cell surface receptors and they belong to the CD2 superfamily of
immunoglobulin domain-containing molecules. The extracellular region of the SLAMF mem-
bers is characterized by the presence of one variable (V)-Ig like and by one constant (C2)-Ig
like domain, with the exception of SLAMF3 which is composed of four Ig-like domains (two
variable and two constant) [13, 14]. A unique feature of the SLAMF members is that they act
as self-ligands and they interact in a homophilic manner, with the exception of SLAMF2 that
associates with SLAMF4.
All SLAMF members, apart from SLAMF2, which is structurally a glycophosphatidylino-
sitol (GPI) membrane anchor without cytoplasmic tail, and SLAMF9 [14], contain a cyto-
plasmic domain characterized by the presence of one to four intracellular switch motif
amino acid sequences (ITSM). Upon SLAMF engagement, the ITSM sequence recruits with
high affinity the SLAM-associated protein (SAP) or EAT-2 and mediates downstream
signaling.
Previous limited reports suggested an altered expression of isolated SLAMF protein on the
surface of T and/or B cells from SLE patients compared to healthy controls (SLAMF1[15],
SLAMF3 [16], SLAMF4 [17, 18], SLAMF6 [19, 20] and SLAMF7 [18]). However, a more
detailed characterization of all SLAMF in the same patient material and in immune cell subsets
has not been reported.
In this communication we systematically assess the cell-surface expression of SLAMF1-7 on
peripheral blood mononuclear cells isolated from patients with SLE and healthy controls sub-
jects. More specifically we examined the expression of SLAMF molecules on T cells, B cells
and monocytes and then further assessed SLAMF expression in a more detailed manner on
the surface of differentiated CD4+T cells, CD8+ T cells and B cells subsets, in an attempt to
identify new subpopulations that may contribute to the pathogenesis of SLE. We report aber-
rant expression of all but SLAMF5 and SLAMF6 in immune cell subsets from patients with
SLE.
Material and methods
Human SLE and control cells
All patients with SLE (n = 48) included in this study were diagnosed according to the Ameri-
can College of Rheumatology classification criteria [21]. Patients with SLE were recruited from
the Division of Rheumatology at Beth Israel Medical Center and provided written consent, as
approved by the Institutional Review Board of Beth Israel Deaconess Medical Center, in com-
pliance with Helsinki Declaration. Age-, sex-, and ethnicity-matched healthy individuals were
chosen as controls (n = 12–20). Disease activity score for the patients with SLE was measured
using the SLEDAI scoring system (Table 1)
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Cell isolation
Peripheral blood was collected in heparin-lithium tubes from the study subjects. Peripheral
blood mononuclear cells (PBMC) were enriched by density gradient centrifugation (Lympho-
cyte Separation Medium, Corning Life Sciences). PBMC were cryopreserved in liquid nitrogen
until analysis.
Antibodies
The following antibodies were used for FACS staining: PE/Cy7 conjugated anti-CD3 (clone
UCHT1), PerCP conjugated anti-CD8 (clone RPA-T8), APC conjugated anti-CD45RA (clone
HI100), Alexa Fluor 488 conjugated anti-CCR7 (clone G043H7), PE/Dazzle 594 conjugated
anti-CD19 (clone HIB19), Alexa Fluor 700 conjugated anti-CD14 (clone HCD14), PerCP con-
jugated anti-CD19 (clone HIB19), Alexa Fluor 488 conjugated anti-CD20 (clone 2H7), Bril-
liant Violet 510 conjugated anti-CD38 (clone HB-7), PE/Cy7 conjugated anti-CD24 (clone
ML5), Brilliant Violet 421 conjugated CD27 (clone M-T271), Alexa Fluor 647 conjugated anti-
IgD (clone IA6-2), PE conjugated anti-SLAMF1/CD150 (clone A12), PE conjugated anti-
SLAMF2/CD48 (clone BJ40), PE conjugated anti-SLAMF3/CD229 (clone HLy-9.1.25), PE
conjugated anti-SLAMF4/CD244 (clone C1.7), PE conjugated anti-SLAMF5/CD84 (clone
CD84.1.21), PE conjugated anti-SLAMF6/CD352 (clone NT-7), PE conjugated anti-SLAMF7/
CD319 (clone 162), APC/Brilliant Violet 421/PE conjugated Mouse IgG1 Isotype Control
(clone MOPC-21) were purchased from Biolegend. PerCP eFLuor 710 conjugated anti-CD4
(clone SK3) was purchased from eBioscience.
Table 1. Characteristics of patients with SLE included in the study.


















Mycophenolate Mofetil—(%) 19 (39.6)
Azathioprine—(%) 9 (18.8)
Methotrextate—(%) 2 (4.2)
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Cell staining
Cryopreserved blood peripheral mononuclear cells were stained for dead cells using the Zom-
bie Aqua or UV Fixable Viability Kit (Biolegend), and then labeled with the mentioned surface
antibodies. Data were acquired on a LSR II SORP (5 lasers, BD Bioscience) and analyzed using
FlowJo (version 10.0.8, FlowJo Enterprise).
Statistics
Kruskal Wallis was performed followed by correction for multiple comparisons using the
Holm-Sidak method. Statistical analyses were performed using GraphPad Prism (version 6).
Statistical significance was reported as follows: p<0.05,  p<0.01,  p<0.001.
Results
We examined the expression of SLAMF members (SLAMF1-7) on the surface of PBMC iso-
lated from SLE patients and age-, sex-, ethnicity- matched healthy controls. The SLAMF
expression was initially assessed on total T cells, CD4+T cells, CD8+T cells, double negative
T cells (DNT, CD3+CD4-CD8-), B cells and monocytes. By assessing the expression of CCR7
and CD45RA on T cells we were able to distinguish the following differentiated CD4+ and
CD8+ T cells subsets: naïve (CCR7+CD45RA+), central memory (CM, CCR7+CD45RA-) and
effector memory (EM, CCR7-CD45RA-), as well as terminally differentiated effector memory
CD8+ T cells (TDEM, CD8+CCR7-CD45RA+) (S1A Fig). The various B cell subsets were
identified based on the expression of CD27, IgD, CD24 and CD38: naïve B cells (CD27-IgD+),
unswitched memory (USM, CD27+IgD+), switched memory (SM, CD27+IgD-) and double
negative B cells (DNB, CD27-IgD-). By gating on naïve B cells and staining with CD24 and
CD38 we were able to define transitional B cells (CD24hiCD38hi) and by gating on switched
CD27+IgD- cells we defined CD24-CD38+ plasmablasts (S1B Fig).
SLAMF1
SLAMF1 expression is more pronounced on T cells. B cells also express SLAMF1, albeit at
lower levels compared to T cells, whereas no SLAMF1 expression was seen in monocytes, in
agreement with previously reported data (Table 2, Fig 1A and S2A Fig) [3]. Among total T
cells, SLAMF1 is primarily expressed by CD4+ and double negative CD3+CD4-CD8-. CD8+ T
cells from healthy individuals were also positive for SLAMF1, but levels of expression were
lower compared to CD4+ and double negative T cells (Table 2, Fig 1A and S2A Fig).
In patients with SLE, we detected a significant up-regulation of SLAMF1 on the cell-surface
of both total T cells and B cells (Table 2, Fig 1A and S2A Fig). Among T cells, SLAMF1 up-reg-
ulation was mainly observed on SLE CD4+ T cells, but not on SLE CD8+ or double negative T
cells compared to normal donors (Table 2, Fig 1A and S2A Fig). On both SLE and healthy
CD4+ T cells, highest SLAMF1 expression was observed on the EM differentiated subset, with
SLE CD4+ EM and CM T cells expressing significantly higher SLAMF1 levels compared to
healthy controls (Table 2, Fig 2A and S2B Fig).
Increased SLAMF1 expression was also seen on SLE naïve, EM and TDEM CD8+ T cells
compared to healthy donors (Table 2, Fig 2A and S2B Fig). We then assessed the expression
profile of SLAMF1 on the cell surface of peripheral blood B cells subsets in SLE patients and
controls. As previously reported, SLAMF1 expression tended to diminish as B cells progress
into unswitched and switched memory differentiated subset, with switched memory B cells
presenting the lowest levels of expression of SLAMF1[3]. A significant increase in SLAMF1
SLAMF expression in PBMC from patients with SLE
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expression was evident in total SLE B cells and was more pronounced in the naïve B cell com-
partment (Table 2, Fig 3A and S2C Fig).
We did not establish any correlation between SLAMF1 expression levels and disease activity
or specific disease manifestations in our cohort of SLE patients, although a higher number of
study subjects may be needed in order to be able to draw any definitive conclusions with
respect to clinical implications.
SLAMF2
Expression of SLAMF2 characterizes all peripheral blood hematopoietic cells. Highest
SLAMF2 expression (two to three-fold difference compared to T cells and monocytes) was
observed on B cells on both healthy controls and patients with SLE. A tendency towards
decreased SLAMF2 expression was documented on SLE total B cells, but the difference did not
reach statistical significance (Table 3, Fig 1B and S3A Fig).
On the contrary, SLAMF2 was significantly up-regulated on the cell-surface of both SLE
CD4+ and CD8+ T cells (Table 3, Fig 1B and S3A Fig). A more detailed analysis of SLAMF2
levels on CD4+ and CD8+ T cells subsets revealed that SLAMF2 expression is independent of
the T cells differentiation status. Indeed, SLAMF2 expression levels are comparable among
naïve, CM, EM and TDEM CD4+ or CD8+ T cells. Interestingly, differences in expression
level of SLAMF2 between SLE and healthy controls are observed in most CD4+ and CD8+ T
Table 2. Expression of SLAMF1 on peripheral blood T and B lymphocytes, monocytes and on T and B cell differentiated subsets on healthy
donors and patients with SLE.
SLAMF1
Healthy Donors (n = 12) SLE patients (n = 15) p valueb
Mean MFIa SEM Mean MFI SEM
CD4 1181 92 1982 237 0.040
CD8 580 79 754 83 0.381
DNT 1257 159 1443 160 0.667
B cells 674 65 1296 147 0.008
Monocytes 12 8 10 8 0.872
CD4+ T cells
Naïve 175 33 400 102 0.160
CM 1523 98 2373 198 0.010
EM 2174 155 3168 243 0.013
CD8+ T cells
Naïve 24 12 296 67 0.010
CM 1153 105 1772 106 0.003
EM 1283 142 1366 150 0.695
TDEM 205 62 742 131 0.011
B cells Healthy Donors (n = 15) SLE patients (n = 12) p value
Mean MFI SEM Mean MFI SEM
Transitional 561 74 714 197 0.563
Naive 515 59 954 157 0.045
Unswitched Mem 441 49 636 64 0.103
Switched Mem 267 24 371 50 0.219
DNB 418 57 651 148 0.330
Plasmablasts 725 116 570 89 0.549
a Results are expressed as mean fluorescence intensity (MFI) ± SEM.
b p values 0.05 are considered statistically significant
https://doi.org/10.1371/journal.pone.0186073.t002
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Fig 1. Expression of SLAMF1-7 in lymphocytes and monocytes from healthy individuals and patients with SLE. SLAMF1-7
expression levels were assessed by flow cytometry in PBMC subpopulations from healthy individuals and patients with SLE. Cumulative
results of SLAMF expression in CD4+, CD8+, DNT cells, B cells and monocytes are shown for (A) SLAMF1, (B) SLAMF2, (C) SLAMF3, (D)
SLAMF4, (E) SLAMF5, (F) SLAMF6 and (G) SLAMF7. Results are expressed as mean MFI ± SEM or mean percentage (%) ± SEM, as
indicated.
https://doi.org/10.1371/journal.pone.0186073.g001
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Fig 2. SLAMF1-7 expression in peripheral blood T cell differentiated subpopulations from healthy donors and patients with SLE.
Cumulative results of SLAMF expression on CD4+ (naïve, EM and CM) and CD8+ (naïve, EM, CM and TDEM) as assessed by flow
cytometry are shown for (A) SLAMF1, (B) SLAMF2, (C) SLAMF3, (D) SLAMF4, (E) SLAMF5, (F) SLAMF6 and (G) SLAMF7. Results are
expressed as mean MFI±SEM or mean percentage (%) ± SEM, as indicated.
https://doi.org/10.1371/journal.pone.0186073.g002
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cells differentiated subsets (Table 3, Fig 2B and S3B Fig). No differences were observed among
SLE patients and controls when we assessed the expression of SLAMF2 on the cell surface of
differentiated peripheral blood B cell subsets (Table 3, Fig 3B and S3C Fig).
SLAMF3
SLAMF3 is expressed on almost all hematopoietic cells, with the exception of CD14+ mono-
cytes. SLAMF3 is highly expressed on T cells from both healthy donors and SLE patients. B
Fig 3. SLAMF1-7 expression in peripheral blood B cell differentiated subpopulations from healthy donors and patients with SLE.
Cumulative results of SLAMF expression on transitional, naïve, unswitched memory, switched memory, double negative B cells and
plasmablasts are shown for (A) SLAMF1, (B) SLAMF2, (C) SLAMF3, (D) SLAMF5 and (E) SLAMF6. Results are expressed as mean
MFI ± SEM
https://doi.org/10.1371/journal.pone.0186073.g003
SLAMF expression in PBMC from patients with SLE
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cells are also positive for SLAMF3, albeit levels of expression are lower compared to that of T
cells (Fig 1C and S4A Fig).
In a very small cohort of SLE patients, a slightly increased expression of SLAMF3 has been
described on SLE CD4+ T cells compared to healthy controls [20]. In our cohort of patients,
we observed only a slight non-statistically significant upregulation of SLAMF3 on the cell sur-
face of CD4+ T cells from patients with SLE compared to normal individuals whereas no dif-
ferences were documented for CD8+, double negative T cells and B cells among SLE patients
and controls (Fig 1C and S4A Fig). A more careful analysis of SLAMF3 expression in CD4+
and CD8+ T cells differentiated subsets revealed a SLAMF3 up-regulation on the cell surface
of naïve SLE CD4+ and CD8+ T cells (Fig 2C and S4B Fig). In both SLE patients and healthy
donors, SLAMF3 is up-regulated as CD4+ and CD8+ T cells progress from naïve to CM and
EM differentiated status. However, no differences were noted regarding SLAMF3 expression
levels in CM and EM CD4+ and CD8+ T cells among patients with SLE and healthy controls
(Fig 2C and S4B Fig).
Further analysis of SLAMF3 levels on naïve, unswitched memory, switched memory and
double negative B cells also revealed no differences between normal controls and SLE patients
(Fig 3C and S4C Fig).
Table 3. Expression of SLAMF2 on peripheral blood T and B lymphocytes, monocytes and on T and B cell differentiated subsets on healthy
donors and patients with SLE.
SLAMF2
Healthy Donors (n = 12) SLE patients (n = 15) p valueb
Mean MFIa SEM Mean MFI SEM
CD4 2899 194 4929 497 0.009
CD8 2328 159 4023 458 0.015
DNT 2308 169 3606 388 0.028
B cells 15022 1235 12997 864 0.182
Monocytes 4945 206 6338 581 0.098
CD4+ T cells
Naïve 2497 144 4346 457 0.010
CM 3319 212 5689 600 0.010
EM 2646 175 4693 517 0.010
CD8+ T cells
Naïve 2427 148 4662 527 0.008
CM 3361 207 5803 614 0.010
EM 2299 154 3414 371 0.020
TDEM 1574 111 2983 351 0.010
B cells Healthy Donors (n = 13) SLE patients (n = 7–9) p value
Mean MFI SEM Mean MFI SEM
Transitional 6455 919 9921 1684 0.320
Naive 4579 608 4003 326 0.720
Unswitched Mem 10618 1435 7876 1239 0.584
Switched Mem 5620 998 3126 445 0.320
DNB 3223 480 2350 364 0.584
Plasmablasts 3588 677 2998 343 0.720
a Results are expressed as mean fluorescence intensity (MFI) ± SEM.
b p values 0.05 are considered statistically significant
https://doi.org/10.1371/journal.pone.0186073.t003
SLAMF expression in PBMC from patients with SLE
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SLAMF4
Presence of SLAMF4 mainly characterizes CD8+ T cells, DNT cells and monocytes. A small
percentage (approximately 5%) of CD4+ T cells is also positive for SLAMF4, whereas B cells
are SLAMF4 negative (Table 4, Fig 1D and S5A Fig).
SLAMF4 levels increased over CD8+ T cells differentiation in healthy donors: approxi-
mately 48% of CM CD8+ T cells and almost all EM and TDEM CD8+ T cells are positive for
SLAMF4, whereas naïve CD8+ T cells are SLAMF4 negative cells (Table 4, Fig 2D and S5B
Fig). Among CD4+ T cells, naïve and CM are SLAMF4 negative, while approximately 10% of
the EM differentiated CD4+ T cells express SLAMF4 (Table 4 Fig 2D and S5B Fig). As previ-
ously described [22], the frequency of CD8+SLAMF4+ T cells is significantly reduced in
patients with SLE. This reduction is mostly apparent on CD8+ CM and EM SLE T cells
(Table 4, Fig 2D and S5B Fig). In addition, the frequency of SLAMF4+CD3+CD4-CD8- dou-
ble negative cells is decreased in the peripheral blood of patients with SLE (Table 4, Fig 1D and
S5A Fig).
SLAMF5
All circulating hematopoietic cells express SLAMF5, with highest levels of expression being
documented on monocytes (Fig 1E and S6A Fig).
Naïve CD4+ T cells express relatively low levels of SLAMF5, but SLAMF5 increased on the
cell surface of CM and EM CD4+ T cells in both healthy donors and patients with SLE (Fig 2E
and S6B Fig). Naïve CD8+ T cells display slightly higher levels of SLAMF5 compared to naïve
CD4+ T cells and, as in CD4+ T cells, SLAMF5 expression increased over cell differentiation
(Fig 2E and S6B Fig). Circulating B cells also express high levels of SLAMF5. Highest levels of
SLAMF5 expression among B cells differentiated subsets were seen on unswitched memory B
cells (Fig 3D and S6C Fig). We detected no differences on SLAMF5 among patients with SLE
Table 4. Expression of SLAMF4 on peripheral blood T and B lymphocytes, monocytes and on T cell differentiated subsets on healthy donors and
patients with SLE.
SLAMF4
Healthy Donors (n = 12–22) SLE patients (n = 14–25) p valueb
Mean (%)a SEM Mean (%) SEM
CD4 5.0 1.4 3.6 1.9 0.925
CD8 56.4 2.6 45.1 3.7 0.025
DNT 77.2 4.3 55.7 5.0 0.0000020
B cells 0.6 0.1 0.2 0.1 0.944
Monocytes 99.0 0.3 95.3 2.2 0.856
CD4+ T cells
Naïve 1.1 0.4 0.9 0.3 1.000
CM 1.3 0.3 1.2 0.4 1.000
EM 11.7 2.4 5.0 1.6 0.232
CD8+ T cells
Naïve 2.5 0.9 2.3 0.8 1.000
CM 48.4 3.9 37.8 4.4 0.014
EM 85.8 2.4 75.7 4.4 0.020
TDEM 93.2 1.7 88.6 2.6 0.563
a Results are expressed as mean percentage (%) ± SEM.
b p values 0.05 are considered statistically significant
https://doi.org/10.1371/journal.pone.0186073.t004
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and healthy controls on none of the cell populations we examined (Figs 1E, 2E and 3D and
S6 Fig).
SLAMF6
SLAMF6 is strongly expressed on the cell surface of both T cells and B cells, but cannot be
found on monocytes (Fig 1F and S7A Fig).
On both CD4+ and CD8+ T cells levels of SLAMF6 progressively increase as cells progress
into their differentiation status. Highest levels of SLAMF6 expression are seen among CM and
EM subsets of CD4+ and CD8+ T cells (Fig 2F and S7B Fig). Despite previous reports showing
that SLAMF6 is up-regulated on the cell surface of SLE CD4+ T cells [20] in a small cohort of
SLE patients, we were not able to detect any differences in our cohort among SLE patients and
healthy controls. Highest level of SLAMF6 expression was observed on total B cells and its lev-
els appear to remain stable on the differentiated subsets of circulating B cells (Figs 1F and 3E
and S7C Fig), without any differences among SLE patients and normal controls.
SLAMF7
As with SLAMF4, expression of SLAMF7 mainly characterizes CD8+ and DNT cells, and is
present only on a very small proportion (less than 5%) of CD4+ T cells (Table 5, Fig 1G and
S8A Fig).
Its levels of expression are low on naïve CD8+ T cells. Approximately 3% of naïve CD8+ T
cells express SLAMF7 (Table 5, Fig 2G and S8B Fig). As naïve CD8+ T cells differentiate into
CM and EM cells, SLAMF7 expression progressively increases. In healthy controls, approxi-
mately 40% of CM CD8+ T cells, 70% of EM CD8+ and 80% of TDEM CD8+ T cells are
SLAMF7 positive (Table 5, Fig 2G and S8B Fig). With respect to CD4+ T cells, less than 10%
of healthy EM CD4+ T cells express SLAMF7. In SLE we observed a significant decrease in the
Table 5. Expression of SLAMF7 on peripheral blood T and B lymphocytes, monocytes and on T cell differentiated subsets on healthy donors and
patients with SLE.
SLAMF7
Healthy Donors (n = 11–21) SLE patients (n = 15–26) p valueb
Mean (%)a SEM Mean (%) SEM
CD4 4.7 1.3 2.9 1.1 0.663
CD8 54.7 3.3 38.8 3.9 0.019
DNT 70.8 4.5 47.8 4.2 0.006
B cells 5.5 1.2 5.7 1.1 0.959
Monocytes 11.7 1.9 10.9 2.3 0.959
CD4+ T cells
Naïve 1.7 0.2 1.2 0.2 0.257
CM 1.8 0.3 1.1 0.2 0.145
EM 11.3 3.8 4.2 1.5 0.188
CD8+ T cells
Naïve 3.1 0.8 3.3 0.8 0.885
CM 47.5 3.3 33.7 3.0 0.024
EM 76.6 2.9 63.4 3.3 0.029
TDEM 86.9 2.9 73.4 3.6 0.033
a Results are expressed as mean percentage (%) ± SEM.
b p values 0.05 are considered statistically significant
https://doi.org/10.1371/journal.pone.0186073.t005
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frequency of SLAMF7 expressing double negative and CD8+ T cells populations (Table 5, Fig
1G and S8A Fig). Among CD8+ T cells, decreased SLAMF7 expression was evident on CM
cells, and was even more apparent on SLE EM and TDEM CD8+ T cells, compared to normal
controls (Table 5, Fig 2G and S8B Fig). As far as B cells are concerned, we were not able to
detect SLAMF7 on the cell surface of peripheral blood total B cells isolated from healthy con-
trols or patients with SLE, despite previously published reports (Table 5, Fig 1G and S8A Fig)
[23].
Discussion
Adaptive immunity plays an important role in immunopathogenesis of SLE. In this context, T
and B cells play an important role in this process [1, 2]. Full T cell and B cell activation requires
recognition of antigen via the cognate antigenic receptor (TCR and BCR respectively), fol-
lowed by a second signal provided via co-stimulatory receptors. The best characterized co-
stimulatory pathways for T cell activation involves the engagement of CD28 to CD80 and
CD86, and for B cell activation the interaction of CD40L to CD40. However, other molecules
may also contribute to optimal T cell and/or B cell activation and differentiation. During
recent years, the SLAMF receptors have emerged as important immunoregulatory molecules
implicated in autoimmunity. Their involvement in SLE was initially suggested by genome-
wide linkage analysis studies performed in SLE affected families in which the 1q23 locus on
chromosome 1, where the SLAMF gene cluster is located, was identified as a lupus susceptibil-
ity locus. Moreover, data from recent studies have unveiled the existence of SNPs and poly-
morphisms of SLAMF molecules associated with SLE and/or specific lupus manifestations [9,
10, 24]. Aberrant expression of various SLAMF molecules has also been reported in SLE
patients [18, 22, 25, 26].
In this study we performed a systematic analysis of the expression pattern of SLAMF1-7 on
peripheral blood cells involved in adaptive immunity. Therefore, we examined the expression
of SLAMF1-7 on monocytes, T cells, B cells and their respective differentiated subsets isolated
from the peripheral blood of patients with SLE. Our findings are of particular interest regard-
ing the expression levels of SLAMF1, SLAMF2, SLAMF4 and SLAMF7. We found a significant
up-regulation of SLAMF1 on the cell surface of both T cells and B cells in patients with SLE, in
agreement with previously published data [15]. In SLE T cells, up-regulation in SLAMF1 levels
was mostly evident in differentiated CD4+ CM and EM subsets, yet a tendency towards
increased SLAMF1 levels was already apparent in the naïve CD4+ compartment. SLE B cells
presented with higher SLAMF1 levels compared to healthy controls, a difference that was
mostly evident in the naïve B cell compartment. Although the pathophysiological significance
of this finding in SLE remains to be determined, SLAMF1 engagement on healthy human B
cells has been shown to promote B cell proliferation and Ig production [27]. Regarding T cells,
SLAMF1 ligation on human T cell clones has been shown to induce IL-2-independent, cyclo-
sporine A-sensitive proliferation and to promote IFN-gamma production [28].
SLAMF2 is structurally different compared to other SLAMF members in the sense that it is
a glycophosphatidylinositol (GPI) membrane anchor without cytoplasmic tail. Despite the lack
of an intracellular domain, SLAMF2 is capable of eliciting downstream signaling upon interac-
tion with SLAMF4 or CD2 [29], although how signaling is mediated remains unclear. An
increase in SLAMF2 mRNA levels has been previously described for SLE CD4+ T cells [30].
We found a significant up-regulation of SLAMF2 on the cell surface of SLE CD4+ and CD8
+ T cells that was evident on all differentiated subsets, even naïve CD4+ and CD8+ T cells. It
has been proposed that the primary function of the SLAMF2:CD2 interaction is to facilitate
adhesion and to secure the distance between T cells and antigen presenting cells for optimal
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antigen presentation [31]. Moreover, SLAMF2 constitutes a central component of the lipid
rafts. SLAMF2 ligation has been shown to be able to amplify early TCR-initiated responses by
facilitating actin cytoskeleton reorganization and recruitment of associated lipid rafts to the
TCR associated activation cap [32]. Freshly isolated SLE T cells are characterized by faster
actin polymerization kinetics compared to normal T cells, as well as by the presence of pre-
clustered lipid rafts that are enriched for activated Syk and the common γ chain of the Fcε
receptor (FcεRγ) [33]. Alterations described in the lipid raft signaling machinery in SLE T
cells may contribute to the hyperactivity that characterizes lupus T cells [33]. Whether
increased SLAMF2 expression facilitates lipid raft clustering on SLE T cells or whether target-
ing SLAMF2 can disrupt lipid raft formation, therefore correcting aberrant signaling responses
in lupus, remains to be examined.
In patients with SLE, the expression profile pattern of SLAMF4 and SLAMF7 is of particular
interest in the CD8+ T cell compartment. Normally, both molecules increase on the cell sur-
face of healthy CD8+ T cells as they progress into differentiation to CM and EM cells. How-
ever, the frequency of SLAMF4+ and SLAMF7+ CD8+ T cells is significantly reduced in
patients with SLE. Both SLAMF4 and SLAMF7 characterize CD8+ T cells with cytotoxic
capacity [22, 34]. Additionally, in patients with SLE the viral-specific antigenic responses of
SLAMF4+ and SLAMF7+ CD8+ T cells are defective [22, 35, 36]. The loss of the SLAMF4+
and SLAMF7+ memory CD8+ T cell population may account for the increased rate of infec-
tions, the leading cause of mortality in SLE.
For SLAMF3, SLAMF5 and SLAMF6 we were not able to identify any substantial differ-
ences in expression levels among healthy controls and patients with SLE. However, as was
illustrated for SLAMF3 [16], the possibility remains that their function is not intact in lupus.
The intracellular region of SLAMF molecules, with the exception of SLAMF2, contains at least
one ITSM sequence that binds with high affinity to either SAP or EAT-2. Reduced, but not
absent, SAP levels have been described for SLE T cells and this decrease may interfere with
proper signal transduction upon SLAMF:SLAMF engagement [37].
SLAMF molecules could present potential therapeutic targets in autoimmunity. SLAMF3
co-engagement on CD4+ T cells with the use of a specific monoclonal antibody, enhances
CD4+ T cells sensitivity to IL-2 and favors regulatory T-cell polarization [16]. Moreover,
despite reduced SLAMF7 levels in lupus CD8+ T cells, targeting SLAMF7 allowed to enhance
anti-viral cytotoxic responses in patients with SLE [34]. As the need for new drugs and treat-
ment strategies in SLE remains mandatory, further understanding the potential involvement
of SLAMF molecules in lupus immunopathogenesis may lead to the development of novel
therapeutic options.
Supporting information
S1 Fig. Gating strategy. Representative flow panels and gating strategy of peripheral blood
mononuclear cells isolated from healthy controls and patients with SLE. (A) T cells:
CD3+CD19-; B cells: CD3-CD19+; CD4+ T cells: CD3+CD4+CD19-; CD8+ T cells:
CD3+CD8+CD19-; double negative T cells (DNT): CD3+CD4-CD8-; monocytes: CD14+;
naïve CD4+ or CD8+ T cells: CCR7+CD45RA+; central Memory (CM) CD4+ or CD8+ T
cells: CCR7+CD45RA-; effector memory (EM) CD4+ or CD8+ T cells: CCR7-CD45RA-;
terminally differentiated effector memory CD8+ T cells (TDEM): CCR7-CD45RA+. (B)
Lymphocytes are defined as in (A) (upper panel). B cells are defined as CD19+CD20+ cells.
Naïve B cells: IgD+CD27-; unswitched memory B cells (USM): IgD+CD27+; switched mem-
ory B cells (SM): IgD-CD27+; double negative B cells (DNB): IgD-CD27-; transitional B
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cells: IgD+CD27-CD24hiCD38hi; plasmablasts: IgD-CD27+CD24-CD38+.
(TIF)
S2 Fig. Expression of SLAMF1 on peripheral blood T and B lymphocytes, monocytes
and on T and B cell differentiated subsets on healthy donors and patients with SLE.
SLAMF1 expression was assessed by flow cytometry on (A) CD4+, CD8+, Double negative
T cells (DNT), B cells and monocytes, (B) T cell differentiated subsets and (C) B cell
differentiated subsets. CM = central memory; EM = effector memory; TDEM = Terminally
Differentiated Effector Memory; USM = unswitched memory; DNB = double negative B
cells.
(TIF)
S3 Fig. Expression of SLAMF2 on peripheral blood T and B lymphocytes, monocytes and
on T and B cell differentiated subsets on healthy donors and patients with SLE. SLAMF2
expression was assessed by flow cytometry on (A) CD4+, CD8+, Double negative T cells
(DNT), B cells and monocytes, (B) T cell differentiated subsets and (C) B cell differentiated
subsets. CM = central memory; EM = effector memory; TDEM = Terminally Differentiated
Effector Memory; USM = unswitched memory; DNB = double negative B cells.
(TIF)
S4 Fig. Expression of SLAMF3 on peripheral blood T and B lymphocytes, monocytes and
on T and B cell differentiated subsets on healthy donors and patients with SLE. SLAMF3
expression was assessed by flow cytometry on (A) CD4+, CD8+, Double negative T cells
(DNT), B cells and monocytes, (B) T cell differentiated subsets and (C) B cell differentiated
subsets. CM = central memory; EM = effector memory; TDEM = Terminally Differentiated
Effector Memory; USM = unswitched memory; DNB = double negative B cells.
(TIF)
S5 Fig. Expression of SLAMF4 on peripheral blood T and B lymphocytes, monocytes and
on T cell differentiated subsets on healthy donors and patients with SLE. SLAMF4 expres-
sion was assessed by flow cytometry on (A) CD4+, CD8+, Double negative T cells (DNT), B
cells and monocytes, (B) T cell differentiated subsets. CM = central memory; EM = effector
memory; TDEM = Terminally Differentiated Effector Memory; USM = unswitched memory;
DNB = double negative B cells.
(TIF)
S6 Fig. Expression of SLAMF5 on peripheral blood T and B lymphocytes, monocytes and
on T and B cell differentiated subsets on healthy donors and patients with SLE. SLAMF5
expression was assessed by flow cytometry on (A) CD4+, CD8+, Double negative T cells
(DNT), B cells and monocytes, (B) T cell differentiated subsets and (C) B cell differentiated
subsets. CM = central memory; EM = effector memory; TDEM = Terminally Differentiated
Effector Memory; USM = unswitched memory; DNB = double negative B cells.
(TIF)
S7 Fig. Expression of SLAMF6 on peripheral blood T and B lymphocytes, monocytes and
on T and B cell differentiated subsets on healthy donors and patients with SLE. SLAMF6
expression was assessed by flow cytometry on (A) CD4+, CD8+, Double negative T cells
(DNT), B cells and monocytes, (B) T cell differentiated subsets and (C) B cell differentiated
subsets. CM = central memory; EM = effector memory; TDEM = Terminally Differentiated
Effector Memory; USM = unswitched memory; DNB = double negative B cells.
(TIF)
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S8 Fig. Expression of SLAMF7 on peripheral blood T and B lymphocytes, monocytes and
on T cell differentiated subsets on healthy donors and patients with SLE. SLAMF7 expres-
sion was assessed by flow cytometry on (A) CD4+, CD8+, Double negative T cells (DNT), B
cells and monocytes, (B) T cell differentiated subsets. CM = central memory; EM = effector
memory; TDEM = Terminally Differentiated Effector Memory; USM = unswitched memory;
DNB = double negative B cells.
(TIF)
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